HemaSphere
(Aug 2023)
PB2138: ORAL REGIMEN SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY ASSESSMENT AND OPTIMIZATION
- Juan Du,
- Haiyan He,
- Xiangqiang Fan,
- Lina Jin,
- Jing Lu,
- Wanting Qiang,
- Jin Liu
Affiliations
- Juan Du
- 1 Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China, Department of Hematology, China
- Haiyan He
- 1 Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China, Department of Hematology, China
- Xiangqiang Fan
- 1 Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China, Department of Hematology, China
- Lina Jin
- 1 Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China, Department of Hematology, China
- Jing Lu
- 1 Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China, Department of Hematology, China
- Wanting Qiang
- 1 Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China, Department of Hematology, China
- Jin Liu
- 1 Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China, Department of Hematology, China
- DOI
-
https://doi.org/10.1097/01.HS9.0000975316.44667.ed
- Journal volume & issue
-
Vol. 7
p.
e44667ed
WeChat QR code